Phageolytix, Inc.
Phageolytix develops bacteriophage-based solutions to address antimicrobial resistance. Activities described on the site include isolation, identification and purification of bacteriophages, genomic sequencing and analysis, discovery and formulation of phage cocktails for wound and respiratory infections, development of phage-infused dressings, and technology licensing.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Phage cocktails for wound infections
Combined bacteriophage formulations intended to target bacterial pathogens in wound infections.
Phage cocktails for respiratory infections
Phage combinations aimed at respiratory pathogens implicated in bronchiectasis, cystic fibrosis, and hospital-acquired infections.
Phage-infused dressings
Topical dressing products formulated to deliver bacteriophages to wound sites.
Phage cocktails for wound infections
Combined bacteriophage formulations intended to target bacterial pathogens in wound infections.
Phage cocktails for respiratory infections
Phage combinations aimed at respiratory pathogens implicated in bronchiectasis, cystic fibrosis, and hospital-acquired infections.
Phage-infused dressings
Topical dressing products formulated to deliver bacteriophages to wound sites.
Services
Identification and combination of bacteriophages into cocktails targeted to specific bacterial pathogens for wound and respiratory indications.
Formulation of bacteriophage-containing dressings or topical products intended for wound infection management.
Sequencing and characterization of phage genomes to support discovery, safety assessment, and documentation.
Management of licensing arrangements and external partnerships for technology transfer and commercialization of phage technologies.
Identification and combination of bacteriophages into cocktails targeted to specific bacterial pathogens for wound and respiratory indications.
Formulation of bacteriophage-containing dressings or topical products intended for wound infection management.
Sequencing and characterization of phage genomes to support discovery, safety assessment, and documentation.
Management of licensing arrangements and external partnerships for technology transfer and commercialization of phage technologies.
Expertise Areas
- Phage therapy research
- Antimicrobial resistance solutions
- Bacteriophage genomics
- Wound-care therapeutics
Key Technologies
- Bacteriophage isolation and purification
- Phage cocktail formulation
- Phage-infused dressing formulation
- Whole genome sequencing of phages
News & Updates
Announcement reporting an exclusive worldwide license grant from a university to the company for phage therapy technology.
Publication providing the complete genome sequence of a novel Pseudomonas aeruginosa phage.
Publication providing the complete genome sequence of a Pseudomonas aeruginosa phage isolated from human lung.
Publication discussing phage therapy approaches for Mycobacterium abscessus and potential strategies to improve clinical outcomes.
Announcement reporting an exclusive worldwide license grant from a university to the company for phage therapy technology.
Publication providing the complete genome sequence of a novel Pseudomonas aeruginosa phage.
Publication providing the complete genome sequence of a Pseudomonas aeruginosa phage isolated from human lung.
Publication discussing phage therapy approaches for Mycobacterium abscessus and potential strategies to improve clinical outcomes.